NET/NEC — Various Sites

VariousWHO Vol. 10

Endocrine & Neuroendocrine System

Prognosis

This section is being prepared by our editorial process.

🔬 Histological Types

📚 Latest Research

2026-09-10

Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy.

Silva BT, et al

A case report from the Archives of Endocrinology and Metabolism describes a pregnant patient with metastatic neuroendocrine tumor of the ileocecal valve complicated by carcinoid syndrome who safely continued lanreotide therapy throughout pregnancy under multidisciplinary supervision, with no maternal complications and confirmed disease stability postpartum. The newborn experienced transient neonatal hyperbilirubinemia requiring phototherapy but showed normal development at 18-month follow-up. The patient had previously received 177Lu-DOTATATE peptide receptor radionuclide therapy and debulking surgery, making this one of the few reported cases addressing pregnancy after such treatment. This report provides supportive observational evidence that lanreotide continuation during pregnancy may be feasible in carefully selected patients, while underscoring the need for close multidisciplinary monitoring and peri-delivery planning for carcinoid crisis.

Archives of endocrinology and metabolism

Source →

2026-09-09

Tumour-to-Kidney Absorbed Dose Ratios for Alpha-Emitter PRRTs Estimated with [177Lu]Lu-DOTATATE SPECT Images and Biokinetic Models: Patient Variations Impact Contribution from Redistributing Daughters.

Kvassheim M, et al

A dosimetry modelling study of 14 neuroendocrine tumour patients treated with [177Lu]Lu-DOTATATE found that alpha-emitter peptide receptor radionuclide therapies (PRRTs) using 212Pb, 225Ac, and 227Th produced large inter-patient variation in kidney absorbed dose when radioactive daughter redistribution was included (absolute coefficient of variation >40%), whereas 226Ac and 230U showed highly consistent kidney doses across patients (absolute CoV <3%). Tumour-to-kidney absorbed dose ratios tended to increase with the physical half-life of the parent radionuclide, suggesting a potential dosimetric advantage for longer-lived alpha-emitters, though this benefit must be weighed against the degree to which released daughter nuclides escape the tumour and irradiate healthy tissue. These findings highlight that representative patient cohorts are essential when evaluating 212Pb, 225Ac, and 227Th as clinical PRRT candidates, because individual patient pharmacokinetics can substantially alter the kidney dose burden predicted by biokinetic models.

International journal of radiation oncology, biology, physics

Source →

2026-09-09

Notch1 supports proliferation and bioenergetic activity in a pancreatic neuroendocrine neoplasm cell line.

Forsythe SD, et al

Researchers have identified Notch1 signaling as a key driver of both cell proliferation and bioenergetic activity in a pancreatic neuroendocrine neoplasm (panNEN) cell line, suggesting it plays a functionally important role in tumor growth. The study used in vitro models to dissect how Notch1 supports the metabolic and proliferative demands of panNEN cells, providing mechanistic insight into a pathway that could be exploited therapeutically. These findings add to the growing understanding of the molecular underpinnings of pancreatic NETs, a heterogeneous group of tumors for which targeted treatment options remain limited. Notch1 may represent a novel actionable target worthy of further investigation in preclinical and clinical settings for this cancer type.

Cancer letters

Source →